Sanofi (SNY) AI Stock Analysis

• Market Cap: $120.69B
• Dividend Yield: 4.47%
• Average Volume (3M): 2.28M
• Price to Earnings (P/E): 12.3
• Beta (1Y): 0.46
• Revenue Growth: -9.32%
• EPS Growth: 120.62%
• Country: US
• Employees: 82,878
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 1.69
• Shares Outstanding: 2,454,938,000
• 10 Day Avg. Volume: 2,268,688
• 30 Day Avg. Volume: 2,283,242
• PEG Ratio: 11.30
• Price to Book (P/B): 1.50
• Price to Sales (P/S): 2.63
• P/FCF Ratio: 19.80
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $63.50
• Price Target Upside: 27.69% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 75 Outperform
• Price Target: $56.00 ▲(12.61% Upside)

Sanofi's overall stock score reflects its strong earnings performance and attractive valuation, which are the most significant factors. The company's financial stability and positive earnings call guidance further support the score, despite some technical analysis indicators suggesting a neutral trend.

Positive Factors

Strong Product Portfolio

Dupixent's strong sales performance highlights Sanofi's robust product portfolio, which is crucial for sustaining long-term revenue growth and market leadership.

Strategic Partnerships

The expanded partnership with Medidata enhances Sanofi's clinical research capabilities, supporting innovation and potentially accelerating new product development.

Financial Stability

A low debt-to-equity ratio indicates financial stability, providing Sanofi with the flexibility to invest in growth opportunities and weather economic uncertainties.

Negative Factors

Declining Vaccine Sales

Declining vaccine sales due to competitive pressures could impact Sanofi's revenue diversification and long-term growth in this crucial segment.

Regulatory Challenges

Regulatory issues at manufacturing facilities can lead to production delays and increased costs, potentially affecting Sanofi's supply chain and market reputation.

Legal Risks

Legal challenges related to drug efficacy disclosures can result in financial penalties and damage to Sanofi's brand, affecting long-term trust and market position.

Sanofi Business Overview & Revenue Model

Company Description

Sanofi (SNY) is a global healthcare company headquartered in France, specializing in the research, development, manufacturing, and marketing of pharmaceutical products and vaccines. The company operates in several key sectors, including prescription pharmaceuticals, consumer healthcare, and vaccines, focusing on therapeutic areas such as diabetes, oncology, immunology, and rare diseases. Sanofi is known for its innovative drug portfolio, which includes both established medications and cutting-edge treatments, as well as a robust vaccine division that addresses public health needs worldwide.

How the Company Makes Money

Sanofi generates revenue primarily through the sale of prescription pharmaceuticals, vaccines, and consumer healthcare products. The company earns significant income from its diverse portfolio of patented drugs, which includes treatments for chronic conditions like diabetes and oncology products. Additionally, Sanofi's vaccines division is a major contributor to its revenue, providing immunizations against diseases such as influenza and meningitis. The company also engages in strategic partnerships and collaborations with other pharmaceutical and biotech firms, enhancing its research capabilities and expanding its product offerings. These collaborations often involve shared development costs and potential profits from newly developed therapies. Furthermore, Sanofi benefits from its presence in emerging markets, where rising healthcare needs and increasing access to medications contribute to growth in sales.

Sanofi Financial Statement Overview

Summary

Sanofi demonstrates financial stability with strong profitability and a solid balance sheet. The income statement shows healthy margins, but revenue growth is slightly negative. The balance sheet is robust with low leverage, while cash flow generation shows some weakness due to a decline in free cash flow growth.

Income Statement

Sanofi's income statement shows moderate performance with a stable gross profit margin of 71% TTM. The net profit margin improved to 14.4% TTM, indicating efficient cost management. However, revenue growth is slightly negative compared to the previous year, reflecting potential challenges in market expansion. EBIT and EBITDA margins are healthy at 18.5% and 23.0% TTM, respectively.

Balance Sheet

Sanofi maintains a solid balance sheet with a debt-to-equity ratio of 0.28, reflecting low leverage and financial stability. The return on equity (ROE) is strong at 8.5% TTM, demonstrating effective use of shareholder funds. The equity ratio stands at 56.1% TTM, indicating a robust capital structure with sufficient equity backing.

Cash Flow

Sanofi's cash flow analysis reveals a decline in free cash flow growth, falling by 73% TTM, which could constrain future investments. However, the operating cash flow to net income ratio is robust at 0.56, showcasing healthy cash conversion from profits. The free cash flow to net income ratio is lower at 0.25, signaling room for improvement in cash retention.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	43.13B	44.29B	41.62B	40.56B	39.17B	37.37B
Gross Profit	30.89B	31.08B	28.99B	28.68B	26.92B	25.21B
EBITDA	9.47B	11.03B	11.39B	13.51B	11.54B	17.88B
Net Income	9.13B	5.56B	5.40B	8.37B	6.22B	12.29B
Balance Sheet
Total Assets	124.96B	132.80B	126.46B	126.72B	120.24B	114.41B
Cash, Cash Equivalents and Short-Term Investments	15.36B	7.93B	8.71B	12.74B	10.10B	13.91B
Total Debt	22.29B	17.91B	18.70B	21.21B	22.41B	23.68B
Total Liabilities	54.68B	54.94B	52.11B	51.57B	51.21B	51.16B
Stockholders Equity	70.01B	77.51B	74.04B	74.78B	68.68B	63.11B
Cash Flow
Free Cash Flow	2.09B	5.89B	8.64B	8.32B	8.48B	5.33B
Operating Cash Flow	2.09B	9.08B	10.26B	10.53B	10.52B	7.45B
Investing Cash Flow	-776.00M	-4.41B	-6.20B	-2.08B	-7.30B	3.59B
Financing Cash Flow	-592.00M	-5.76B	-8.05B	-5.82B	-7.06B	-6.49B

Sanofi Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 49.73
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNY, the sentiment is Negative. The current price of 49.73 is below the 20-day moving average (MA) of 50.31, below the 50-day MA of 49.81, and below the 200-day MA of 50.25, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 46.99 is Neutral, neither overbought nor oversold. The STOCH value of 29.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNY.

Sanofi Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NVS	80 Outperform	$253.41B	17.90	32.93%	3.02%	11.53%	-15.21%
GILD	77 Outperform	$152.13B	19.36	40.53%	2.59%	2.76%	6407.19%
PFE	77 Outperform	$148.00B	15.17	10.59%	6.61%	4.44%	128.96%
MRK	76 Outperform	$250.41B	13.53	39.51%	3.25%	1.59%	58.02%
SNY	75 Outperform	$120.69B	12.32	8.39%	4.47%	-9.32%	120.62%
BMY	69 Neutral	$106.16B	17.61	33.84%	4.76%	1.26%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Sanofi Corporate Events

Sanofi Advances with Dupixent and Teizeild Approvals in November 2025

In November 2025, Sanofi announced significant advancements in its pharmaceutical offerings. On November 7, 2025, Sanofi, in collaboration with Regeneron, revealed that their drug Dupixent met all primary and secondary endpoints in a pivotal phase 3 study for allergic fungal rhinosinusitis (AFRS), leading to the acceptance of a supplemental biologics license application for FDA priority review. This marks a potential new indication for Dupixent, which could become the first treatment specifically approved for AFRS. Additionally, on November 14, 2025, Sanofi’s drug Teizeild received a recommendation for EU approval for patients with stage 2 type 1 diabetes. These developments highlight Sanofi’s ongoing commitment to expanding its treatment portfolio and enhancing its market position in the pharmaceutical industry.

Sanofi Issues $3 Billion in Notes to Bolster Financial Strategy

On November 3, 2025, Sanofi announced the issuance of $3 billion in notes, including floating and fixed rate notes due in 2027, 2028, and 2032. This strategic financial move is expected to enhance Sanofi’s capital structure and support its long-term growth objectives, potentially impacting its market position and providing liquidity for future investments.

Sanofi’s Efdoralprin Alfa Achieves Key Milestones in AATD Emphysema Study

On October 22, 2025, Sanofi announced that its investigational drug, efdoralprin alfa, met all primary and key secondary endpoints in a phase 2 study for alpha-1 antitrypsin deficiency (AATD) emphysema. The drug showed superiority over standard plasma-derived therapy, offering less frequent dosing and maintaining higher functional AAT levels, which could significantly improve treatment convenience for patients. These results highlight the potential of efdoralprin alfa as a restorative recombinant therapy, reinforcing Sanofi’s commitment to addressing unmet medical needs in rare and respiratory conditions. The study’s positive outcomes may enhance Sanofi’s industry positioning and offer new hope to stakeholders in the AATD community.

Sanofi Successfully Prices $3 Billion Bond Issue

On October 28, 2025, Sanofi announced the successful pricing of a $3 billion bond issue across five tranches, with proceeds intended for general corporate purposes. This strategic financial move, coordinated by major financial institutions, is expected to support Sanofi’s operational capabilities and strengthen its position in the biopharmaceutical industry.

Sanofi Releases H1 2025 Financial Results

Sanofi has released its condensed half-year consolidated financial statements for the six months ending June 30, 2025, along with information on its financial results for the first half and third quarter of 2025. The report highlights a decrease in total assets from December 2024 to June 2025, indicating potential challenges in asset management or strategic adjustments. This financial disclosure provides stakeholders with insights into Sanofi’s financial health and operational performance during the first half of the year.

Sanofi Reports Strong Q3 2025 Growth and Strategic Advances

In its Q3 2025 report, Sanofi announced a 7.0% increase in sales at constant exchange rates, driven by strong performances from new pharma launches and Dupixent, despite a decline in vaccine sales. The company achieved significant milestones, including regulatory approvals for Wayrilz and Tzield, and completed the acquisition of Vigil Neuroscience. Sanofi’s strategic focus on science and patient-centric solutions contributed to its continued growth, with plans to complete a €5 billion share buyback by the end of 2025, reinforcing its commitment to delivering shareholder value.

Sanofi Faces EU Setback for Rezurock Amidst Positive Developments

In October 2025, Sanofi faced a setback when the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion on the marketing authorization application for Rezurock, a treatment for chronic graft-versus-host disease. Despite this, Sanofi remains committed to pursuing approval, citing strong clinical and real-world evidence supporting Rezurock’s efficacy and safety. Additionally, Sanofi’s Wayrilz received a positive recommendation for EU approval to treat immune thrombocytopenia, and their high-dose influenza vaccine showed superior protection for older adults. Sanofi’s Tzield was also accepted for expedited review in the US for stage 3 type 1 diabetes, highlighting the company’s ongoing efforts to expand its therapeutic offerings.

Sanofi’s AlphaMedix Achieves Key Efficacy Endpoints in Phase 2 Study

On October 8, 2025, Sanofi announced that its investigational therapy AlphaMedixTM (212Pb-DOTAMTATE) met all primary efficacy endpoints in a phase 2 study for treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The study showed clinically meaningful benefits in both PRRT-naïve and PRRT-exposed patients, with a manageable safety profile. These results highlight the potential of Targeted Alpha Therapy with lead-212 as a new treatment option, reinforcing Sanofi’s commitment to innovative cancer therapies. The findings will be discussed with health authorities and presented at the 2025 European Society for Medical Oncology Congress.

Sanofi’s SAR446268 Gains Fast Track Designation and Boosts Biotech Investments

In September 2025, Sanofi announced that its gene therapy SAR446268 received fast track designation from the US FDA for treating non-congenital myotonic dystrophy type 1, a rare genetic disorder with no approved treatments. This designation aims to expedite the development of SAR446268, which uses RNA interference to target the DMPK gene, potentially addressing key symptoms of the disease. Additionally, Sanofi committed an additional $625 million to Sanofi Ventures to boost investments in biotech and digital health innovation, reinforcing its strategic focus on advancing healthcare solutions.

Sanofi’s Dupixent Advances in EU with Positive CHMP Opinion

On September 22, 2025, Sanofi and Regeneron announced that their drug Dupixent received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the treatment of chronic spontaneous urticaria (CSU) in adults and adolescents. If approved, Dupixent would be the first targeted medicine for CSU in the EU in over a decade. This advancement could enhance Sanofi’s market position in the EU and provide new treatment options for patients with CSU who have inadequate responses to existing therapies.

Sanofi’s Tzield Gains Approval in China for Type 1 Diabetes

In September 2025, Sanofi announced significant advancements in their product offerings. On September 10, 2025, Tzield was approved in China as the first disease-modifying therapy for stage 2 type 1 diabetes, marking a new era in diabetes care by delaying the onset of stage 3 T1D. This approval aligns with Chinese guidelines emphasizing the protection of beta-cell function. Additionally, on September 11, 2025, Sanofi’s SAR402663 received fast track designation in the US for treating neovascular age-related macular degeneration, enhancing their position in the ophthalmology sector. Furthermore, on September 17, 2025, Sanofi reported positive phase 2a study results for brivekimig in treating hidradenitis suppurativa, underscoring their commitment to addressing unmet medical needs.

Sanofi’s Amlitelimab Shows Promising Results in Atopic Dermatitis Study

On September 4, 2025, Sanofi announced positive results from its COAST 1 phase 3 study, revealing that amlitelimab met all primary and key secondary endpoints in treating moderate-to-severe atopic dermatitis. Amlitelimab, a monoclonal antibody targeting OX40-ligand, showed significant efficacy in skin clearance and disease severity, with potential for dosing only four times a year. These findings highlight amlitelimab’s promise as a differentiated treatment option, supporting Sanofi’s ambition to advance in the atopic dermatitis market.

Sanofi’s Wayrilz Gains FDA Approval as First BTK Inhibitor for ITP

On August 29, 2025, Sanofi announced that the US FDA approved Wayrilz (rilzabrutinib) as the first Bruton’s tyrosine kinase (BTK) inhibitor for adults with persistent or chronic immune thrombocytopenia (ITP) who have not responded to previous treatments. This approval, based on the LUNA 3 phase 3 study, highlights Wayrilz’s potential to improve platelet counts and quality of life for over 25,000 US adults with ITP. The approval underscores Sanofi’s expertise in rare and immunological diseases, potentially positioning Wayrilz as a treatment of choice for ITP, enhancing Sanofi’s market presence in the field of rare blood disorders.

Sanofi’s Rilzabrutinib Gains EU Orphan Designation for IgG4-Related Disease

On August 14, 2025, Sanofi announced that its investigational drug rilzabrutinib received orphan designation from the European Medicines Agency for treating IgG4-related disease, a rare immune-mediated condition. This designation highlights Sanofi’s commitment to advancing treatments for rare diseases. The drug, which showed positive results in a Phase 2 study, is also under regulatory review in the US, EU, and China for immune thrombocytopenia, with a US FDA decision expected by August 29, 2025.